In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites

Biotechnology Journal

Volumn 9, Issue 6, 2014, Pages 844-851

  Woisetschläger, Max ^a   Antes, Bernhard ^a   Borrowdale, Radha ^a   Wiederkum, Susanne ^a   Kainer, Manuela ^a   Steinkellner, Herta ^b   Wozniak Knopp, Gordana ^b   Moulder, Kevin ^a   Rüker, Florian ^b   Mudde, Geert C ^a  

^a Babraham Research Campus   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

ADCC; CD16a; Fc fragment; Human tumor xenograft; Immunotherapy

Indexed keywords

BINDING SITES; CELLS; CYTOLOGY; EPITOPES; MONOCLONAL ANTIBODIES;

ADCC; CD16A; FC FRAGMENT; HUMAN TUMORS; IMMUNOTHERAPY;

TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; IMMUNOGLOBULIN FC FRAGMENT; TRASTUZUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; RECEPTOR, ERBB-2;

ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; EFFECTOR CELL; HEK293 CELL LINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN ENGINEERING; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMALS; BINDING SITES; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HEK293 CELLS; HUMANS; IMMUNOLOGY; IN VITRO TECHNIQUES; METABOLISM; MICE; NEOPLASM TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE; CELL PROLIFERATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IN VITRO TECHNIQUES; MICE; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2;

EID: 84901657291     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201300387     Document Type: Article

References (28)

1. Yarden, Y., The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37Suppl.4, S3-8.
2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J. et al., Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
3. Kern, J. A., Slebos, R. J., Top, B., Rodenhuis, S. et al., C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest. 1994, 93, 516-520.
4. Liu, L., Shao, X., Gao, W., Bai, J. et al., The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-analysis of published data. J. Thorac. Oncol. 2010, 5, 1922-1932.
5. Matsubara, J., Yamada, Y., Hirashima, Y., Takahari, D. et al., Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin. Cancer Res. 2008, 14, 3022-3029.
6. Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H. E., Muller, W., HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell. Oncol. 2010, 32, 57-65.
7. Yu, G. Z., Chen, Y., Wang, J. J., Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: Their relationship with clinicopathological parameters and prognostic significance. J. Cancer Res. Clin. 2009, 135, 1331-1339.
8. Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A. et al., c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000, 18, 2201-2209.
9. Shepard, H. M., Jin, P., Slamon, D. J., Pirot, Z., Maneval, D. C., Herceptin. Handb. Exp. Pharmacol. 2008, 183-219.
10. Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L. et al., Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 2006, 94, 259-267.
11. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M. et al., p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 1989, 9, 1165-1172.
12. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F. et al., Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61, 4744-4749.
13. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M. et al., Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61, 4892-4900.
14. Badache, A., Hynes, N. E., A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004, 5, 299-301.
15. Adams, C. W., Allison, D. E., Flagella, K., Presta, L. et al., Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. CII 2006, 55, 717-727.
16. Valabrega, G., Montemurro, F., Aglietta, M., Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007, 18, 977-984.
17. Thery, J. C., Spano, J. P., Azria, D., Raymond, E., Penault Llorca, F., Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur. J. Cancer 2014, 50, 892-901.
18. Wozniak-Knopp, G., Bartl, S., Bauer, A., Mostageer, M. et al., Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 2010, 23, 289-297.
19. Durocher, Y., Perret, S., Kamen, A., High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002, 30, E9.
20. Sondermann, P., Huber, R., Oosthuizen, V., Jacob, U., The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000, 406, 267-273.
21. Kainer, M., Antes, B., Wiederkum, S., Wozniak-Knopp, G. et al., Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab). Arch. Biochem. Biophys. 2012, 526, 154-158.
22. Petricevic, B., Laengle, J., Singer, J., Sachet, M. et al., Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J. Transl. Med. 2013, 12, 307-317.
23. Junttila, T. T., Akita, R. W., Parsons, K., Fields, C. et al., Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15, 429-440.
24. Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W. et al., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62, 4132-4141.
25. Ghetie, M. A., Podar, E. M., Ilgen, A., Gordon, B. E. et al., Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 1997, 94, 7509-7514.
26. Wolff, E. A., Schreiber, G. J., Cosand, W. L., Raff, H. V., Monoclonal antibody homodimers: Enhanced antitumor activity in nude mice. Cancer Res. 1993, 53, 2560-2565.
27. Harwerth, I. M., Wels, W., Schlegel, J., Muller, M., Hynes, N. E., Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 1993, 68, 1140-1145.
28. Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A. et al., Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 1991, 88, 8691-8695.